Syndax Pharmaceuticals Inc·4

Mar 17, 6:01 AM ET

Metzger Michael A 4

4 · Syndax Pharmaceuticals Inc · Filed Mar 17, 2025

Insider Transaction Report

Form 4
Period: 2025-03-14
Metzger Michael A
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Stock options (Right to buy)

    2025-03-14+6,0740 total
    Exercise: $7.20Exp: 2025-06-01Common Stock (6,074 underlying)
  • Exercise/Conversion

    Common Stock

    2025-03-14$7.20/sh+6,074$43,733306,195 total
Footnotes (1)
  • [F1]This option is fully vested.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4